Cargando…

The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression

High grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBCL-DH) represents an uncommon B-cell lymphoma (BCL) with aggressive clinical courses and poor prognosis. Despite revolutionary therapeutic advances in BCL, there has been limited treatment progress in HGBCL-DH, thus necessitating additi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Manman, Tan, Jinshui, Fan, Ziying, Pham, Lan V., Zhu, Feng, Fang, Xiaosheng, Zhao, Haijun, Young, Kenh, Xu, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613613/ https://www.ncbi.nlm.nih.gov/pubmed/37899423 http://dx.doi.org/10.1038/s41598-023-45721-z

Ejemplares similares

The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
por: Leal, Ana S., et al.
Publicado: (2020)

P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
por: Watts, Justin M., et al.
Publicado: (2023)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
por: Yi, Joanna S., et al.
Publicado: (2021)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
por: Baker, Emma K, et al.
Publicado: (2015)

IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma
por: Buhe, Hada, et al.
Publicado: (2022)

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
por: Harding, James J., et al.
Publicado: (2023)

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
por: Rosen, Joshua C., et al.
Publicado: (2021)

Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
por: Trkulja, Kyla L., et al.
Publicado: (2023)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
por: Koblish, Holly, et al.
Publicado: (2018)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
por: Yue, Eddy W., et al.
Publicado: (2017)

Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies
por: Alavi, Afsaneh, et al.
Publicado: (2022)

Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis
por: Ou, Ling, et al.
Publicado: (2022)

FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma
por: Wang, Bo, et al.
Publicado: (2018)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
por: Binder, Adam F., et al.
Publicado: (2023)

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma
por: Gusyatiner, Olga, et al.
Publicado: (2021)

Design and Characterization of Bivalent BET Inhibitors
por: Tanaka, Minoru, et al.
Publicado: (2016)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer
por: Jin, Xin, et al.
Publicado: (2019)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

Identification of Novel Covalent XPO1 Inhibitors Based on a Hybrid Virtual Screening Strategy
por: Shen, Zheyuan, et al.
Publicado: (2022)

The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2010)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
por: Turner, Joel G., et al.
Publicado: (2016)

Discovering Anti-platelet Drug Combinations with an Integrated Model of Activator-Inhibitor Relationships, Activator-Activator Synergies and Inhibitor-Inhibitor Synergies
por: Lombardi, Federica, et al.
Publicado: (2015)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ghf8ru6g0ciqf94blk25530k7t